Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
TherapeuticsMD, Inc. (often abbreviated as TXMD) was a U.S.-based pharmaceutical company focused on developing and commercializing products exclusively for women. Their portfolio addressed various stages of a woman's life, including FDA-approved products for menopausal hormone therapy (like IMVEXXY® and BIJUVA®) and a contraceptive (ANNOVERA®). The company aimed to advance women's health by providing innovative solutions. In early 2023, Mayne Pharma Group Limited completed the acquisition of key assets from TherapeuticsMD, significantly altering its operational landscape.
This facility served as the central hub for corporate leadership, administrative operations, strategic planning, and oversight of research, development, and commercialization activities before the asset sale to Mayne Pharma.
The headquarters was situated in a modern office park, likely offering contemporary amenities and a professional setting conducive to a pharmaceutical company's operations. Specific architectural highlights are not widely publicized.
As a company focused on women's health, the culture likely emphasized innovation, scientific rigor, patient-centricity, and collaboration among its teams dedicated to research, clinical development, and bringing products to market.
The Boca Raton headquarters was significant as it was the nerve center for all of TherapeuticsMD's operations, from product development strategy to market launch and financial management during its time as an independent entity.
Prior to its asset acquisition by Mayne Pharma, TherapeuticsMD's primary commercial focus was the United States market. While they may have explored international partnerships or out-licensing opportunities for their products, their direct operational and sales presence was predominantly U.S.-centric. Global functions would have included regulatory strategy for potential ex-U.S. filings and business development activities exploring international markets.
951 Yamato Road, Suite 220
Boca Raton
Florida
USA
Address: N/A
Field-based teams supported commercial product launches, physician engagement, and market access on a regional basis across the United States.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, TherapeuticsMD' leadership includes:
TherapeuticsMD has been backed by several prominent investors over the years, including:
The most significant executive changes at TherapeuticsMD occurred in conjunction with the acquisition of its key assets by Mayne Pharma Group Limited, completed in early 2023. This event led to the departure or transition of most of the then-current executive team as the company's structure and operations were fundamentally altered.
Discover the tools TherapeuticsMD uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition, TherapeuticsMD likely used common corporate email formats. The most probable formats would include first initial followed by last name, or first name separated by a dot from the last name, at their domain therapeuticsmd.com. These emails are likely no longer active.
[first_initial][last]@therapeuticsmd.com (e.g., jdoe@therapeuticsmd.com) or [first].[last]@therapeuticsmd.com (e.g., jane.doe@therapeuticsmd.com)
Format
rfinizio@therapeuticsmd.com
Example
65%
Success rate
Mayne Pharma Press Release • January 4, 2023
Mayne Pharma Group Limited announced it has completed the acquisition of the license for three US FDA-approved women’s health products, ANNOVERA®, IMVEXXY®, BIJUVA® and a portfolio of pre-natal vitamins from TherapeuticsMD, Inc....more
GlobeNewswire (TherapeuticsMD Press Release) • December 12, 2022
TherapeuticsMD, Inc. announced that its stockholders voted to approve the previously announced transaction with Mayne Pharma at a Special Meeting of Stockholders held on December 12, 2022....more
GlobeNewswire (TherapeuticsMD Press Release) • August 09, 2022
TherapeuticsMD, Inc. announced it has entered into definitive agreements to license its products IMVEXXY®, BIJUVA®, ANNOVERA®, and its prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands to Mayne Pharma Group Limited....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including TherapeuticsMD, are just a search away.